MBio believes in a new approach to healthcare, where rapid and accurate diagnostic tests will be run wherever and whenever they are needed, without compromise. MBio’s proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and manufacturing techniques to deliver lab-quality results anywhere in just a few minutes. MBio is launching our first on-the-spot in vitro diagnostic tests to help fight the COVID-19 pandemic, while also developing a portfolio of highly accurate, host-response panels to manage acute infections and sepsis, and next generation tests for heart attack triage. The LightDeck platform is shipping and achieving success in veterinary diagnostics and for environmental testing.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Colorado
Company HQ Country:
United States
Year Founded:
2012
Main Therapeutic Focus:
Diagnostics
Lead Product in Development:
5-minute COVID Serology Test
Development Phase of Primary Product:
Other/Not Applicable
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Looking for distribution partner for COVID screening tests
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
